Tiffany Chang
0000-0002-6046-3256
Publication & Citation Trends
Publications
0 total
Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study OA
Cited by 4
Semantic Scholar
Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial OA
Cited by 60
Semantic Scholar
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study OA
Cited by 28
Semantic Scholar
Emicizumab dose up‐titration in case of suboptimal bleeding control in people with haemophilia A OA
Cited by 12
Semantic Scholar
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies OA
Cited by 35
Semantic Scholar
Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study OA
Cited by 12
Semantic Scholar
Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5) OA
Cited by 54
Semantic Scholar
Channeling effects in the prescription of new therapies: the case of emicizumab for hemophilia A. OA
Cited by 5
Semantic Scholar
Research Topics
Intracerebral and Subarachnoid Hemorrhage Research
(31)
Intracranial Aneurysms: Treatment and Complications
(22)
Acute Ischemic Stroke Management
(21)
Traumatic Brain Injury and Neurovascular Disturbances
(20)
Neurosurgical Procedures and Complications
(20)
Affiliations
Twitter (United States)
Tulane University
Ulsan College
United States Nuclear Regulatory Commission
Texas Medical Center